Back to Journals » Vascular Health and Risk Management » Volume 8

Nebivolol: impact on cardiac and endothelial function and clinical utility

Authors Toblli JE, DiGennaro F, Giani JF, Dominici FP

Received 11 January 2012

Accepted for publication 17 February 2012

Published 13 March 2012 Volume 2012:8 Pages 151—160

DOI https://doi.org/10.2147/VHRM.S20669

Review by Single-blind

Peer reviewer comments 3

Jorge Eduardo Toblli1, Federico DiGennaro1, Jorge Fernando Giani2, Fernando Pablo Dominici2

1Hospital Aleman, 2Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), Facultad de Farmacia y Bioquímica, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina

Abstract: Endothelial dysfunction is a systemic pathological state of the endothelium characterized by a reduction in the bioavailability of vasodilators, essentially nitric oxide, leading to impaired endothelium-dependent vasodilation, as well as disarrangement in vascular wall metabolism and function. One of the key factors in endothelial dysfunction is overproduction of reactive oxygen species which participate in the development of hypertension, atherosclerosis, diabetes, cardiac hypertrophy, heart failure, ischemia-reperfusion injury, and stroke. Because impaired endothelial activity is believed to have a major causal role in the pathophysiology of vascular disease, hypertension, and heart failure, therapeutic agents which modify this condition are of clinical interest. Nebivolol is a third-generation β-blocker with high selectivity for β1-adrenergic receptors and causes vasodilation by interaction with the endothelial L-arginine/nitric oxide pathway. This dual mechanism of action underscores several hemodynamic qualities of nebivolol, which include reductions in heart rate and blood pressure and improvements in systolic and diastolic function. Although nebivolol reduces blood pressure to a degree similar to that of conventional β-blockers and other types of antihypertensive drugs, it may have advantages in populations with difficult-to-treat hypertension, such as patients with heart failure along with other comorbidities, like diabetes and obesity, and elderly patients in whom nitric oxide-mediated endothelial dysfunction may be more pronounced. Furthermore, recent data indicate that nebivolol appears to be a cost-effective treatment for elderly patients with heart failure compared with standard care. Thus, nebivolol is an effective and well tolerated agent with benefits above those of traditional β-blockers due to its influence on nitric oxide release, which give it singular hemodynamic effects, cardioprotective activity, and a good tolerability profile. This paper reviews the pharmacology structure and properties of nebivolol, focusing on endothelial dysfunction, clinical utility, comparative efficacy, side effects, and quality of life in general with respect to the other antihypertensive agents.

Keywords: beta-blockers, nebivolol, oxidative stress, endothelial function, cardiovascular protection, nitric oxide

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Virtual reality simulation for the optimization of endovascular procedures: current perspectives

Rudarakanchana N, Van Herzeele I, Desender L, Cheshire NJW

Vascular Health and Risk Management 2015, 11:195-202

Published Date: 10 March 2015

Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms

Vacek TP, Rehman S, Neamtu D, Yu S, Givimani S, Tyagi SC

Vascular Health and Risk Management 2015, 11:173-183

Published Date: 27 February 2015

Complications of the endovascular management of acute ischemic stroke

Gill HL, Siracuse JJ, Parrack IK, Huang ZS, Meltzer AJ

Vascular Health and Risk Management 2014, 10:675-681

Published Date: 28 November 2014

Lower extremity amputation in peripheral artery disease: improving patient outcomes

Swaminathan A, Vemulapalli S, Patel MR, Jones WS

Vascular Health and Risk Management 2014, 10:417-424

Published Date: 16 July 2014

Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia

Bell DA, Hooper AJ, Watts GF, Burnett JR

Vascular Health and Risk Management 2012, 8:651-659

Published Date: 28 November 2012

The prevention and regression of atherosclerotic plaques: emerging treatments

Kalanuria AA, Nyquist P, Ling G

Vascular Health and Risk Management 2012, 8:549-561

Published Date: 25 September 2012

Use of carvedilol in hypertension: an update

Leonetti G, Egan CG

Vascular Health and Risk Management 2012, 8:307-322

Published Date: 18 May 2012

Percutaneous mechanical thrombectomy for treatment of acute femoropopliteal bypass occlusion

Lichtenberg M, Käunicke M, Hailer B

Vascular Health and Risk Management 2012, 8:283-289

Published Date: 4 May 2012

Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis

Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B

Vascular Health and Risk Management 2012, 8:255-264

Published Date: 23 April 2012